Applications
BMPs are now produced using recombinant DNA technology. Oral and orthopaedic surgery have benefited greatly from commercially available BMP formulations.
In regenerative medicine, BMPs are delivered to the site of the fracture by being incorporated into a bone implant, and released gradually to allow bone formation, as the growth stimulation by BMPs must be localized and sustained for some weeks. Currently, two BMPs products have been approved by the Food and Drug Administration (FDA) for clinical applications (fractures of long bones, intervertebral disk regeneration), by delivery in a purified collagen matrix (which is implanted in the site of the fracture). These are Infuse BMP-2 (Medtronic) and OP-1 BMP-7 (Stryker Biotech). The Infuse product has been approved for certain dental applications as well, but the Medtronic has also been accused of bias and conflict of interest in researching and promoting this product. Though they do work, when artificially implanted into the body, they tend to irritate the skin and muscle tissue around it.
Read more about this topic: Bone Morphogenetic Protein